nach oben

Erschienen in:

18.04.2018 | Multiple Sklerose | zertifizierte fortbildung

Fortschreitender Krankheitsverlauf

Aktuelle Therapien und Zukunftsoptionen für die progrediente Multiple Sklerose

verfasst von: Dr. med. Simon Faissner, Prof. Dr. med. Ralf Gold

Erschienen in: InFo Neurologie + Psychiatrie | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapie der Multiplen Sklerose hat sich in den letzten Jahren durch die Entwicklung neuer Medikamente für die schubförmige Phase der Erkrankung umfangreich gewandelt. Die Entwicklung von Medikamenten bei Progression hingegen war bisher — abgesehen von einem gerade in Europa zugelassenen B-Zell-depletierenden Antikörper — weniger erfolgreich. Im Folgenden werden das Verständnis von pathogenetischen Veränderungen bei Progression, etablierte und aktuell zugelassene Therapieverfahren sowie zukünftig interessante Ziele für neue Behandlungsansätze dargestellt.

Kantarci OH, Lebrun C, Siva A et al. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. Ann Neurol 2016; 79:288–94CrossRef

Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8:647–56CrossRef

Kutzelnigg A, Lucchinetti CF, Stadelmann C et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705–12CrossRef

Nikic I, Merkler D, Sorbara C et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nature medicine 2011; 17:495–9CrossRef

Heppner FL, Greter M, Marino D et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nature medicine 2005; 11:146–52CrossRef

Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. Journal of leukocyte biology 2005; 78:135–43CrossRef

Brundula V, Rewcastle NB, Metz LM et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125:1297–1308CrossRef

Miron VE, Boyd A, Zhao JW et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nature neuroscience 2013; 16:1211–8CrossRef

Koch MW, Zabad R, Giuliani F et al. Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis. Journal of the neurological sciences 2015; 358:131–7CrossRef

10.

Bigaud M, Guerini D, Billich A et al. Second generation S1P pathway modulators: research strategies and clinical developments. Biochimica et biophysica acta 2014; 1841:745–58CrossRef

11.

Choi JW, Gardell SE, Herr DR et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. PNAS 2011; 108:751–6CrossRef

12.

Lublin F, Miller DH, Freedman MS et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016, DOI: 10.1016/s0140-6736(15)01314-8

13.

Kappos L, Bar-Or A, Cree BAC et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391:1263–73CrossRef

14.

Peferoen LA, Breur M, van de Berg S et al. Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice. Immunology 2016; 149:146–56CrossRef

15.

Wong WT. Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Frontiers in cellular neuroscience 2013; 7:22PubMedPubMedCentral

16.

Hametner S, Wimmer I, Haider L et al. Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013; 74:848–61CrossRef

17.

Stephenson E, Nathoo N, Mahjoub Y et al. Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurol 2014; 10:459–68CrossRef

18.

Haider L, Fischer MT, Frischer JM et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134:1914–24CrossRef

19.

Weigel KJ, Lynch SG, LeVine SM. Iron chelation and multiple sclerosis. ASN neuro 2014; 6:e00136PubMedPubMedCentral

20.

Lynch SG, Peters K, LeVine SM. Desferrioxamine in chronic progressive multiple sclerosis: a pilot study. Multiple sclerosis (Houndmills, Basingstoke, England) 1996; 2:157–60CrossRef

21.

Lynch SG, Fonseca T, LeVine SM. A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis. Cellular and molecular biology (Noisy-le-Grand, France) 2000; 46:865–9

22.

Faissner S, Mahjoub Y, Mishra M et al. Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease? Multiple sclerosis (Houndmills, Basingstoke, England) 2017; DOI: 10.1177/1352458517728811

23.

Linker RA, Lee DH, Ryan S et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134:678–92CrossRef

24.

Strassburger-Krogias K, Ellrichmann G, Krogias C et al. Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study. Ther Adv Neurol Disord 2014; 7:232–8CrossRef

25.

Trapp BD, Peterson J, Ransohoff RM et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278–85CrossRef

26.

Sorbara CD, Wagner NE, Ladwig A et al. Pervasive axonal transport deficits in multiple sclerosis models. Neuron 2014; 84:1183–90CrossRef

27.

Craner MJ, Newcombe J, Black JA et al. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. PNAS 2004; 101:8168–73CrossRef

28.

Waxman SG. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nature clinical practice Neurology 2008; 4:159–69CrossRef

29.

Plemel JR, Liu WQ, Yong VW. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nature reviews Drug discovery 2017; DOI: 10.1038/nrd.2017.115CrossRefPubMed

30.

Mei F, Fancy SPJ, Shen YA et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nature medicine 2014; 20:954–60CrossRef

31.

Green AJ, Gelfand JM, Cree BA et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet 2017; 390:2481–9CrossRef

32.

Tourbah A, Lebrun-Frenay C, Edan G et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Multiple sclerosis (Houndmills, Basingstoke, England) 2016; DOI: 10.1177/1352458516667568CrossRefPubMedPubMedCentral

33.

Mi S, Hu B, Hahm K et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nature medicine 2007; 13:1228–33CrossRef

34.

Howell OW, Reeves CA, Nicholas R et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134:2755–71CrossRef

35.

Choi SR, Howell OW, Carassiti D et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135:2925–37CrossRef

36.

Magliozzi R, Howell OW, Reeves C et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68:477–93CrossRef

37.

Hawker K, O’Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460–71CrossRef

38.

Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376:209–20CrossRef

39.

Kappos L, Weinshenker B, Pozzilli C et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63:1779–87CrossRef

40.

Patti F, Messina S, Solaro C et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry 2016; 87:944–51CrossRef

41.

Hoffmann V, Kuhn W, Schimrigk S et al. Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients. European Journal of Neurology 2006; 13:72–6CrossRef

42.

Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. Journal of Advanced Nursing 2006; 56:617–35CrossRef

43.

Gross CC, Schulte-Mecklenbeck A, Klinsing S et al. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3:e183CrossRef

44.

Parodi B, Rossi S, Morando S et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta neuropathologica 2015; 130:279–95CrossRef

45.

Metz LM, Li DKB, Traboulsee AL et al. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. N Engl J Med 2017; 376:2122–33CrossRef

46.

Gentile A, Musella A, Bullitta S et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. Journal of Neuroinflammation 2016; 13:207CrossRef

47.

Allaman I, Fiumelli H, Magistretti PJ et al. Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes. Psychopharmacology 2011; 216:75–84CrossRef

48.

Gilgun-Sherki Y, Panet H, Melamed E et al. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain research 2003; 989:196–204CrossRef

49.

Kalkers NF, Barkhof F, Bergers E et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Multiple sclerosis (Houndmills, Basingstoke, England) 2002; 8:532–33CrossRef

50.

Tran JQ, Rana J, Barkhof F et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm 2014; 1:e18CrossRef

Titel: Fortschreitender Krankheitsverlauf
Aktuelle Therapien und Zukunftsoptionen für die progrediente Multiple Sklerose
verfasst von: Dr. med. Simon Faissner
Prof. Dr. med. Ralf Gold
Publikationsdatum: 18.04.2018
Verlag: Springer Medizin
Schlagwörter: Multiple Sklerose
Ocrelizumab
Mitoxantron
Ocrelizumab
Erschienen in: InFo Neurologie + Psychiatrie / Ausgabe 4/2018
Print ISSN: 1437-062X
Elektronische ISSN: 2195-5166
DOI: https://doi.org/10.1007/s15005-018-2369-4

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Insomnie & Co. müssen auch den Neurologen interessieren

CME: Medikamentöse Behandlungsresistenz bei der Schizophrenie

LIBERTY für Migränepatienten

Erfahrungsaustausch Parkinson

Neue Klassifikation der Kopfschmerzerkrankungen

Koalition gegen psychische Erkrankungen